{"id":937890,"date":"2026-02-18T08:51:22","date_gmt":"2026-02-18T13:51:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-corporate-update-and-reports-half-yearly-2025-26-results\/"},"modified":"2026-02-18T08:51:22","modified_gmt":"2026-02-18T13:51:22","slug":"propanc-biopharma-provides-corporate-update-and-reports-half-yearly-2025-26-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-corporate-update-and-reports-half-yearly-2025-26-results\/","title":{"rendered":"Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025\/26 Results"},"content":{"rendered":"
\n

MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported half yearly financial results as of December 31, 2025 (Year end June 30).<\/p>\n

\n Corporate and R&D Highlights<\/strong>\n <\/p>\n

\n Accelerates IP Momentum: Files Four Provisional Patent Applications \u2013 Strengthening Global Protection for Breakthrough Proenzyme Formulations<\/strong>\n <\/p>\n

Four provisional patent applications were filed with IP Australia detailing two new methods to treat resistant cancer and fibrosis, methods of producing synthetic trypsinogen and chymotrypsinogen, and innovative formulations of trypsinogen and chymotrypsinogen. As these applications advance to national phase entry across major global markets, it is expected to more than double the Company\u2019s IP portfolio \u2014 from approximately 90 to over 200 patents \u2014 covering compositions, formulations, treatment methods, and new therapeutic indications<\/p>\n

\n Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal<\/strong>\n <\/p>\n

The Company and its joint research partners at the Universities of Ja\u00e9n and Granada published key findings in a peer reviewed journal, Scientific Reports, regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The tumor microenvironment (TME) plays a pivotal role in tumor initiation, progression, and the form of pre-metastatic niches. PDAC is characterized by a dense fibrotic stroma containing a significant enriched population of cancer-associated fibroblasts (CAFs). The interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis, underscoring the potential benefits of novel therapeutic strategies targeting stromal cells to improve patient survival. PRP, consisting of two bovine derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, have shown efficacy in cancer treatment. The findings demonstrate PRP exerts multifaceted effects. Results underscore the candidacy of PRP as a potential disruptor of the TME.<\/p>\n

\n Corporate and Financial Updates<\/strong>\n <\/p>\n

\n $100 Million Private Placement Facility<\/strong>\n <\/p>\n

Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1 million investment upon issuance of 100 shares of Series C Convertible Preferred Stock. A further $500,000 investment was received upon exercise of 50 shares of Series C Convertible Preferred Stock.<\/p>\n

\n Q1 Financial Summary (Quarter Ended September 30, 2025)<\/strong>\n <\/p>\n